Published in Neurobiol Dis on June 27, 2007
Perinatal Choline Supplementation Reduces Amyloidosis and Increases Choline Acetyltransferase Expression in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice. PLoS One (2017) 1.39
Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci (2009) 1.33
Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci (2008) 1.12
Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One (2010) 1.11
Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc Natl Acad Sci U S A (2009) 1.02
DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res (2010) 0.96
Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol (2012) 0.95
Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. J Neuropathol Exp Neurol (2013) 0.92
Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective? Cell Mol Life Sci (2008) 0.92
Functional deprivation promotes amyloid plaque pathogenesis in Tg2576 mouse olfactory bulb and piriform cortex. Eur J Neurosci (2010) 0.89
Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis (2010) 0.88
Basal forebrain cholinergic modulation of sleep transitions. Sleep (2014) 0.87
Complete morphologies of basal forebrain cholinergic neurons in the mouse. Elife (2014) 0.86
BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 0.86
IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. PLoS One (2014) 0.85
Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum. Neuroscience (2009) 0.84
Neuroprotective role for galanin in Alzheimer's disease. EXS (2010) 0.83
Effect of neocortical and hippocampal amyloid deposition upon galaninergic and cholinergic neurites in AβPPswe/PS1ΔE9 mice. J Alzheimers Dis (2011) 0.82
Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice. PLoS One (2013) 0.79
Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease. Curr Alzheimer Res (2009) 0.78
Cattle encephalon glycoside and ignotin injection improves cognitive impairment in APPswe/PS1dE9 mice used as multitarget anti-Alzheimer's drug candidates. Neuropsychiatr Dis Treat (2015) 0.78
Limited effects of an eIF2αS51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease. Neural Plast (2015) 0.77
A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One (2014) 0.76
Oral Administration of Gintonin Attenuates Cholinergic Impairments by Scopolamine, Amyloid-β Protein, and Mouse Model of Alzheimer's Disease. Mol Cells (2015) 0.76
Intrinsic Cholinergic Neurons in the Hippocampus: Fact or Artifact? Front Synaptic Neurosci (2016) 0.75
Cholinergic profiles in the Goettingen miniature pig (Sus scrofa domesticus) brain. J Comp Neurol (2016) 0.75
The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. J Psychiatry Neurosci (2017) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES. J Histochem Cytochem (1964) 10.70
The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS (1988) 6.75
Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (1976) 6.09
The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex (1992) 5.57
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem (1975) 4.29
Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci (1999) 3.92
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways. J Neurosci (2004) 3.44
New stereological methods for counting neurons. Neurobiol Aging (1993) 3.41
Induction of autophagy in axonal dystrophy and degeneration. J Neurosci (2006) 3.28
Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience (1983) 3.26
Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 3.18
A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal (1996) 3.18
Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci (1998) 3.03
beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem (2000) 2.96
Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron (1996) 2.89
Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol (1990) 2.78
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci (1996) 2.69
Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.36
Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci (2002) 2.35
Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol (1990) 2.24
Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis (2005) 2.22
Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci (1982) 2.17
Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res (1979) 2.04
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci (2003) 1.91
Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci (2003) 1.81
Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev (2002) 1.80
Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience (2002) 1.73
Hypothesis: interference with axonal transport of neurofilament as a common pathogenetic mechanism in certain diseases of the central nervous system. N Engl J Med (1985) 1.73
Neuritic plaques in senile dementia of Alzheimer type: a Golgi analysis in the hippocampal region. Brain Res (1983) 1.60
Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol (1984) 1.60
Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci (2002) 1.56
In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol (2003) 1.50
Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience (1987) 1.38
Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol (2004) 1.36
Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med (2002) 1.28
TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J Comp Neurol (1994) 1.26
Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci (1999) 1.25
Patterns of aberrant sprouting in Alzheimer's disease. Neuron (1991) 1.24
Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol (1990) 1.23
Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex (1996) 1.22
Abeta associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol (1998) 1.20
Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol (1997) 1.20
Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol Aging (2005) 1.20
Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport (1995) 1.17
Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci U S A (1993) 1.16
PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J Comp Neurol (2003) 1.16
Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol (1989) 1.13
Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci (2004) 1.12
Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci (1999) 1.11
Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci (2002) 1.10
The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging (2005) 1.09
Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci (1995) 1.08
Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci (2005) 1.07
Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology (2003) 1.05
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest (2006) 1.04
A role for TrkA during maturation of striatal and basal forebrain cholinergic neurons in vivo. J Neurosci (1997) 1.02
Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. J Comp Neurol (1989) 1.01
Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann Neurol (1992) 1.00
Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease. Life Sci (1980) 1.00
Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J Biol Chem (2001) 1.00
The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathol Appl Neurobiol (1997) 0.98
Co-localization of vasoactive intestinal polypeptide, gamma-aminobutyric acid and choline acetyltransferase in neocortical interneurons of the adult rat. Brain Res (1997) 0.97
Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem (1988) 0.96
Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol (2001) 0.96
Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol (1999) 0.95
Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol (2007) 0.95
Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum Mol Genet (2001) 0.94
alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology (2005) 0.93
Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease. Proc Natl Acad Sci U S A (1989) 0.93
Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett (2003) 0.92
Cholinergic neuropathology in a mouse model of Alzheimer's disease. J Comp Neurol (2003) 0.91
Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience (2005) 0.91
Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice. Neurobiol Aging (2006) 0.89
Choline acetyltransferase-immunoreactive neurons intrinsic to rodent cortex and distinction from acetylcholinesterase-positive neurons. Neuroscience (1984) 0.89
The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neuroscience (2003) 0.88
Human striatum: the distribution of neurofibrillary tangles in Alzheimer's disease. Brain Res (1994) 0.88
Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience (1994) 0.87
Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport (2001) 0.87
Alzheimer's disease and related dementias: selective involvement of specific neuronal systems. CRC Crit Rev Clin Neurobiol (1985) 0.86
Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease. J Comp Neurol (1993) 0.86
Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res (2003) 0.86
Correlative decrease of large neurons in the neostriatum and basal nucleus of Meynert in Alzheimer's disease. Brain Res (1989) 0.84
Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging. Neurology (1985) 0.84
Cholinergic systems in mammalian brain identified with antibodies against choline acetyltransferase. Neurochem Int (1984) 0.80
Choline acetyltransferase mRNA expression in the striatal neurons of patients with Alzheimer's disease. Neurosci Lett (1997) 0.79
Observations on choline acetyltransferase containing structures in the CD-1 mouse brain. Neurosci Lett (1988) 0.78
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
Chronic traumatic encephalopathy in a National Football League player. Neurosurgery (2005) 4.67
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology (2004) 3.94
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol (2002) 3.07
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 2.97
Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol (2003) 2.70
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA (2009) 2.59
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Chronic traumatic encephalopathy in a national football league player: part II. Neurosurgery (2006) 2.40
Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem (2005) 2.36
Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci (2008) 2.30
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol (2004) 2.21
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci (2003) 2.14
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci (2003) 2.06
Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol (2003) 1.94
Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol (2005) 1.91
Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol (2002) 1.82
Traumatic brain injury--football, warfare, and long-term effects. N Engl J Med (2010) 1.81
Chronic traumatic encephalopathy (CTE) in a National Football League Player: Case report and emerging medicolegal practice questions. J Forensic Nurs (2010) 1.71
Hemoglobin levels and Alzheimer disease: an epidemiologic study in India. Am J Geriatr Psychiatry (2004) 1.69
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci (2002) 1.69
Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem (2006) 1.67
Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci (2003) 1.67
Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc (2005) 1.67
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage (2006) 1.65
Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol (2002) 1.63
Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey. J Am Geriatr Soc (2004) 1.59
Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol (2006) 1.56
Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol (2005) 1.55
Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol (2007) 1.53
Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat (2003) 1.50
Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry (2010) 1.49
Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry (2009) 1.48
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry (2011) 1.48
Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol (2004) 1.48
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods (2008) 1.46
Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol (2007) 1.45
Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol (2013) 1.43
Infection hospitalization increases risk of dementia in the elderly. Crit Care Med (2014) 1.43
Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol (2004) 1.43
Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain. Brain Res Dev Brain Res (2003) 1.43
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res (2005) 1.39
Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol (2007) 1.38
22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem (2003) 1.37
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med (2013) 1.36
The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol (2005) 1.35
Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol (2002) 1.32
Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord (2008) 1.30
Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials (2006) 1.29
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci (2002) 1.24
Caregiving burden and psychiatric morbidity in spouses of persons with mild cognitive impairment. Int J Geriatr Psychiatry (2005) 1.24
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.23
Single cell gene expression profiling in Alzheimer's disease. NeuroRx (2006) 1.22
Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci (2003) 1.22
Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol (2005) 1.21
Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology (2004) 1.21
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci (2009) 1.19
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol (2005) 1.18
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol (2012) 1.16
Single-cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res (2004) 1.16
Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol (2007) 1.16
Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology (2012) 1.15
Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener (2014) 1.15
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14